Partnership will provide Canadians access to the powerful benefits of personalized medicine while strengthening a new Canadian supply chain.
TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Canadian pharmacogenetic (PGx) testing provider, Inagene Diagnostics Inc., has partnered with fellow Canadian health-tech company, Granville Biomedical Inc., to add Canadian researched and developed medical grade swabs to its testing kits, bringing the best of locally manufactured medical products to Canadians.
Inagene Diagnostics Inc.’s PGx test is conducted using an oral cheek (buccal) swab that analyzes a person’s DNA to determine which medications are most compatible for the individual according to their genetic profile. Granville Biomedical Inc., a company specializing in the design of novel medical devices, recently expanded their business to include the research and development of medical grade swabs following the Canadian government’s call at the onset of the pandemic for assistance to produce Made in Canada COVID-19 testing supplies. The funding opportunities that followed, allowed Granville to quickly redirect their efforts from women’s health to the production of Class 1, Canadian-made medical devices. The development of Granville Swab™ also resulted in the creation of a robust domestic supply chain in Canada that Canadian organizations, such as Inagene, can leverage. To align with their Toronto-based lab location, Inagene is committed to promoting Made in Canada quality by continuing to improve their testing kits, with a goal to make the kit a 100% Canadian product by 2022.
"Our Granville team is very inspired by the work that Inagene Diagnostics is doing within the pharmacogenetic testing space, and we are honoured to engage in this collaboration for the purpose of advancing Canadian healthcare,” said Christine Goudie, CEO of Granville Biomedical. “This partnership will foster our domestic supply chain as well as encourage and promote future made-in-Canada healthcare supplies.”
Granville Biomedical is currently working on the development and validation of a uniquely designed oral swab for Inagene to include in their genetic testing kits. The focus of the novel swab is to ensure specimen collection efficacy comparable to existing market leading buccal swabs. The swab will be validated through Health Canada and their associated Class 1 regulatory requirements.
Inagene Diagnostics Inc. was founded to help people with pain and mental health conditions, find more effective treatment, faster. Research shows that 98% of Canadians carry genetic variants that can impact a person’s response to various medications. PGx testing provides valuable insights that allow patients to determine which medication is predicted to work most effectively for them, with the least side effects.
“PGx testing can have a life-changing impact on those living with chronic illnesses,” says Nancy White, CEO of Inagene Diagnostics Inc. “We’re proud to have such a strong innovation partner in the Canadian medical products space, who shares our passion for helping people, to bring the best possible product to Canadians, and support the Canadian healthcare ecosystem.”
About Inagene Diagnostics Inc.
Inagene™ Diagnostics Inc. is a CLIA accredited Canadian pharmacogenetic testing company located in Toronto. Inagene’s Personalized Insights™ tests focus on providing comprehensive and reliable genetic tests to guide drug selection and treatment. Learn more at www.inagene.com
About Granville Biomedical
Granville Biomedical Inc. is a Canadian health-tech company specializing in the design of innovative medical devices and anatomical teaching tools to enhance healthcare training and delivery. Hailing from St. John’s, the company’s Granville Swab™ launched in 2020 for Covid-19 testing purposes, followed by the research and development of a novel oral buccal swab. Learn more at www.granvillebiomedical.ca and www.granvilleswab.ca.
Note to Editors:
For further information, please contact:
Neelam Bance Parsons, Inagene Diagnostics
多伦多，2021年11月1日（环球新闻）--加拿大药物遗传学（PGx）检测提供商Inagene Diagnostics Inc.与加拿大卫生技术公司Granville Biomedical Inc.合作，在其检测试剂盒中添加加拿大研究和开发的医疗级拭子，为加拿大人带来最好的本地制造的医疗产品。
Inagene Diagnostics Inc.的PGx测试是使用口腔颊拭子进行的，该拭子分析一个人的DNA，根据他们的基因特征确定哪些药物最适合个人。格兰维尔生物医学公司（Granville Biomedical Inc.）是一家专门设计新型医疗设备的公司，最近将业务扩大到包括医疗级拭子的研究和开发，此前加拿大政府在疫情爆发时呼吁帮助生产加拿大制造的新冠肺炎测试用品。随后的融资机会使格兰维尔迅速将他们的努力从妇女健康转向生产1类加拿大制造的医疗设备。Granville拭子™的开发也导致了加拿大国内供应链的建立，加拿大组织，如Inagene，可以利用这一供应链。为了配合他们位于多伦多的实验室位置，Inagene致力于通过继续改进他们的测试试剂盒来提高加拿大制造的质量，目标是到2022年使试剂盒100%成为加拿大产品。
Granville Biomedical首席执行官Christine Goudie说：“Inagene Diagnostics在药物遗传学测试领域所做的工作给我们的Granville团队带来了很大的启发，我们很荣幸能参与这项合作，以促进加拿大的医疗保健。这项合作将促进我们国内的供应链，并鼓励和促进未来加拿大制造的医疗保健用品。”
“PGX测试可以对慢性病患者产生改变生活的影响，”Inagene Diagnostics Inc.首席执行官南希·怀特（Nancy White）表示。“我们很自豪在加拿大医疗产品领域有这样一个强大的创新合作伙伴，他们与我们分享帮助人们的热情，为加拿大人带来最好的产品，并支持加拿大医疗保健生态系统。”
Granville Biomedical Inc.是一家加拿大医疗技术公司，专门从事创新医疗设备和解剖学教学工具的设计，以加强医疗保健培训和交付。该公司的格兰维尔拭子™来自圣约翰，于2020年推出，用于新冠肺炎测试，随后研发了一种新型口腔颊拭子。在www.granvillebiomedical.ca和www.granvilleswab.ca了解更多信息。